The quarter came in slightly worse than the market expected. Published estimates were approximately $167.1 million of revenue and a $0.45 adjusted EPS loss; Vital Farms delivered $166.0 million and a $0.47 adjusted loss per share, respectively.
| Metric | Q2 2026 | Q2 2025 | Market expectation |
|---|---|---|---|
| Net revenue | $166.0M (Financial Highlights) | $184.8M (Financial Highlights) | ~$167.1M |
| Adjusted net income (loss) per diluted share | $(0.47) (Adjusted Net Loss Income Reconciliation) | $0.36 (Adjusted Net Loss Income Reconciliation) | ~$(0.45) |
| Gross margin | 6.6% (Financial Highlights) | 38.9% (Financial Highlights) | — |
| Adjusted EBITDA | $(26.6)M (Adjusted EBITDA Reconciliation) | $29.9M (Adjusted EBITDA Reconciliation) | — |
| Net cash used in operating activities, first half | $(45.9)M (Cash Flow statement) | $4.5M (Cash Flow statement) | — |
The operating damage was severe, even if much of it was anticipated. Revenue fell 10.1% year over year, while gross margin collapsed to 6.6% as excess eggs were pushed into low-priced breaker and wholesale channels. Those sales reduced gross profit by $19.5 million, and the quarter also absorbed $0.8 million of farmer-contract amendment amortization and $7.8 million of butter-exit costs (Financial Highlights). Management's claim that underlying margin was better excludes real costs that still consumed cash, so the headline recovery case remains unproven.
The strongest evidence of stabilization is in market share, not earnings. Vital Farms gained more than 200 basis points of retail dollar share while total shell-egg category pricing fell more than 35% year over year (Management discussion). That suggests the brand retained consumer demand despite pricing pressure, but retail revenue still declined to $158.0 million from $176.1 million, so share gains have not yet translated into growth (Revenue discussion).
Liquidity improved, but at the cost of leverage and financial flexibility. The company closed a $125 million term loan and a $60 million asset-based facility, providing access to substantially more borrowing capacity (Financing Update). However, cash and marketable securities fell to $21.2 million from $113.4 million at year-end, first-half operating cash use reached $45.9 million, and debt stood at $30.0 million (Balance Sheet and Cash Flow Highlights). The board also terminated the buyback program after repurchasing $15.0 million of stock in the quarter, removing a capital-return support that was already inconsistent with the company's worsening liquidity (Cash Flow Highlights).
Reaffirming guidance is better than a cut, but it is not an upside revision. Fiscal 2026 revenue remains guided to $775 million-$800 million and adjusted EBITDA to $0 million-$10 million, with the plan depending on positive shell-egg volume growth in the second half and no further competitive deterioration (Fiscal 2026 Outlook). Against a quarter that slightly missed consensus and produced a $26.6 million adjusted EBITDA loss, the filing supports a stabilization narrative rather than a demonstrated recovery; the new financing reduces near-term liquidity risk, but the net result lands modestly below expectations.
Read the original 8-K on SEC EDGAR ↗